- Home
- SKIN vs FBIO Comparison
SKIN vs FBIO Comparison
Compare SKIN & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIN | FBIO |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | 101 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.9M | 104.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SKIN | FBIO |
|---|---|---|
| Price | $0.82 | $2.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.03 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 750.6K | 390.1K |
| Earning Date | 03-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $300,790,000.00 | N/A |
| Revenue This Year | $1.24 | $29.71 |
| Revenue Next Year | $4.73 | $49.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $1.33 |
| 52 Week High | $2.69 | $4.53 |
Technical Indicators
Market Signals| Indicator | SKIN | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 30.10 | 31.99 |
| Support Level | N/A | $2.42 |
| Resistance Level | $1.61 | $2.90 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 2.62 | 2.78 |
Price Performance
Historical ComparisonAbout SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.